Adoption and implementation of new technologies in substance abuse treatment

Paul M. Roman, J Aaron Johnson

Research output: Contribution to journalArticle

150 Citations (Scopus)

Abstract

In addition to clinical outcomes, understanding the adoption and implementation of new treatment interventions is essential. This analysis was designed to assess the predictive utility of organization-level features in understanding the adoption and implementation of new technologies in substance abuse treatment. Naltrexone, which was found to be in current use in 44.1% of a national sample of 400 private substance abuse treatment centers, was selected as an appropriate sample technology for study. Adoption of naltrexone is significantly related to both the treatment center's age and its administrative leadership. Naltrexone adoption is also significantly associated with the percentage of the center's caseload covered by managed care programs and by the percentage of relapsers represented in the caseload. The analysis was less successful in predicting naltrexone implementation for either primary alcohol dependence or primary opiate addiction.

Original languageEnglish (US)
Pages (from-to)211-218
Number of pages8
JournalJournal of Substance Abuse Treatment
Volume22
Issue number4
DOIs
StatePublished - Jun 19 2002
Externally publishedYes

Fingerprint

Naltrexone
Substance-Related Disorders
Technology
Substance Abuse Treatment Centers
Opioid-Related Disorders
Managed Care Programs
Alcoholism
Organizations

Keywords

  • Naltrexone
  • Organizational change
  • Substance abuse treatment
  • Technology transfer

ASJC Scopus subject areas

  • Phychiatric Mental Health
  • Medicine (miscellaneous)
  • Clinical Psychology
  • Psychiatry and Mental health

Cite this

Adoption and implementation of new technologies in substance abuse treatment. / Roman, Paul M.; Johnson, J Aaron.

In: Journal of Substance Abuse Treatment, Vol. 22, No. 4, 19.06.2002, p. 211-218.

Research output: Contribution to journalArticle

@article{342a240c1af346e788844fa864069cb9,
title = "Adoption and implementation of new technologies in substance abuse treatment",
abstract = "In addition to clinical outcomes, understanding the adoption and implementation of new treatment interventions is essential. This analysis was designed to assess the predictive utility of organization-level features in understanding the adoption and implementation of new technologies in substance abuse treatment. Naltrexone, which was found to be in current use in 44.1{\%} of a national sample of 400 private substance abuse treatment centers, was selected as an appropriate sample technology for study. Adoption of naltrexone is significantly related to both the treatment center's age and its administrative leadership. Naltrexone adoption is also significantly associated with the percentage of the center's caseload covered by managed care programs and by the percentage of relapsers represented in the caseload. The analysis was less successful in predicting naltrexone implementation for either primary alcohol dependence or primary opiate addiction.",
keywords = "Naltrexone, Organizational change, Substance abuse treatment, Technology transfer",
author = "Roman, {Paul M.} and Johnson, {J Aaron}",
year = "2002",
month = "6",
day = "19",
doi = "10.1016/S0740-5472(02)00241-6",
language = "English (US)",
volume = "22",
pages = "211--218",
journal = "Journal of Substance Abuse Treatment",
issn = "0740-5472",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Adoption and implementation of new technologies in substance abuse treatment

AU - Roman, Paul M.

AU - Johnson, J Aaron

PY - 2002/6/19

Y1 - 2002/6/19

N2 - In addition to clinical outcomes, understanding the adoption and implementation of new treatment interventions is essential. This analysis was designed to assess the predictive utility of organization-level features in understanding the adoption and implementation of new technologies in substance abuse treatment. Naltrexone, which was found to be in current use in 44.1% of a national sample of 400 private substance abuse treatment centers, was selected as an appropriate sample technology for study. Adoption of naltrexone is significantly related to both the treatment center's age and its administrative leadership. Naltrexone adoption is also significantly associated with the percentage of the center's caseload covered by managed care programs and by the percentage of relapsers represented in the caseload. The analysis was less successful in predicting naltrexone implementation for either primary alcohol dependence or primary opiate addiction.

AB - In addition to clinical outcomes, understanding the adoption and implementation of new treatment interventions is essential. This analysis was designed to assess the predictive utility of organization-level features in understanding the adoption and implementation of new technologies in substance abuse treatment. Naltrexone, which was found to be in current use in 44.1% of a national sample of 400 private substance abuse treatment centers, was selected as an appropriate sample technology for study. Adoption of naltrexone is significantly related to both the treatment center's age and its administrative leadership. Naltrexone adoption is also significantly associated with the percentage of the center's caseload covered by managed care programs and by the percentage of relapsers represented in the caseload. The analysis was less successful in predicting naltrexone implementation for either primary alcohol dependence or primary opiate addiction.

KW - Naltrexone

KW - Organizational change

KW - Substance abuse treatment

KW - Technology transfer

UR - http://www.scopus.com/inward/record.url?scp=0036276127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036276127&partnerID=8YFLogxK

U2 - 10.1016/S0740-5472(02)00241-6

DO - 10.1016/S0740-5472(02)00241-6

M3 - Article

C2 - 12072165

AN - SCOPUS:0036276127

VL - 22

SP - 211

EP - 218

JO - Journal of Substance Abuse Treatment

JF - Journal of Substance Abuse Treatment

SN - 0740-5472

IS - 4

ER -